证券代码：603360 证券简称：百傲化学 公告编号：2023-035 重要内容提示： 大连百傲化学股份有限公司（以下简称"百傲化学"或"公司"）股东大 连三鑫投资有限公司（以下简称"三鑫投资"或"转让方"）拟通过协议转让方 式将其持有的本公司无限售流通股 102,442,508 股股份（占目前公司总股本的 28.42%）以 11.00 元/股的价格转让给大连光曜致新舒鸿企业管理咨询合伙企业 （有限合伙）（以下简称"光曜致新"或"受让方"）。 本次权益变动属于持股 5%以上股东协议转让股份，未触及要约收购。 本次权益变动不会导致公司控股股东及实际控制人发生变化。 鉴于目前三鑫投资所持公司股份存在质押、冻结等权利限制，若无法在 交割前解除其所持股份上的权利限制，上述协议转让股份存在无法过户的风险。 本次权益变动事项尚需取得上海证券交易所合规性审查确认意见，并在 中国证券登记结算有限责任公司上海分公司办理股份转让过户登记手续，相关事 项尚存在不确定性，敬请投资者注意投资风险。 大连百傲化学股份有限公司 关于持股 5%以上股东协议转让公司股份暨权益变动 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚 ...

大连百傲化学股份有限公司 简式权益变动报告书 上市公司名称：大连百傲化学股份有限公司 股票上市地点：上海证券交易所 股票简称：百傲化学 股票代码：603360 信息披露义务人：大连三鑫投资有限公司 注册地址：辽宁省大连市中山区五五路 47 号 1 单元 16 层 通讯地址：辽宁省大连市中山区五五路 47 号 1 单元 16 层 股份变动性质：股份减少（协议转让） 签署日期：二〇二三年八月 信息披露义务人声明 一、本报告书依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司收购管理办法》《公开发行证券公司信息披露内容与格式准则第 15 号——权益变动报告书》及相关的法律、法规编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不 违反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》等规定，本 报告书已全面披露信息披露义务人在大连百傲化学股份有限公司中拥有权益的 股份变动情况。截至本报告书签署之日，除本报告书披露的信息外，上述信息 披露义务人没有通过任何其他方式增加或减少其在大连百傲化学股份有限公司 中拥有权益的股份。 ...

证券代码：603360 证券简称：百傲化学 公告编号：2023-024 大连百傲化学股份有限公司 关于召开 2022 年度业绩说明会预告公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 说明会类型 大连百傲化学股份有限公司（以下简称"公司"）已于 2023 年 04 月 29 日发 布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经 营成果、财务状况，公司计划于 2023 年 06 月 15 日下午 15:00-16:30 以视频直 播结合网络文字互动形式举行 2022 年度业绩说明会，在信息披露允许的范围内 就投资者关心的问题进行交流。 二、 说明会召开的时间、地点和方式 （一）会议召开时间：2023 年 06 月 15 日 下午 15:00-16:30 （二）会议召开地点：上证路演中心（网址：http://roadshow.sseinfo.com/） （三）会议召开方式：视频直播和网络文字互动 会议召开时间：2023 年 06 月 15 日(星期四) 下午 15: ...

Financial Performance - The company's operating revenue for 2022 was CNY 1,256,659,912.76, representing a 24.88% increase compared to CNY 1,006,261,506.68 in 2021[21] - The net profit attributable to shareholders for 2022 was CNY 402,565,517.91, a 60.71% increase from CNY 250,491,543.06 in the previous year[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 399,418,246.97, up 57.58% from CNY 253,476,610.27 in 2021[21] - The net cash flow from operating activities for 2022 was CNY 479,900,179.76, a significant increase of 237.90% compared to CNY 142,025,131.28 in 2021[21] - Basic earnings per share increased to CNY 1.61, reflecting a growth of 61.00% compared to the previous year[22] - The diluted earnings per share rose to CNY 1.60, marking a 61.62% increase year-on-year[22] - The weighted average return on equity improved to 32.07%, an increase of 6.95 percentage points from the previous year[22] Assets and Dividends - The total assets at the end of 2022 were CNY 1,754,392,289.92, reflecting a 5.01% increase from CNY 1,670,722,296.11 at the end of 2021[21] - The net assets attributable to shareholders at the end of 2022 were CNY 1,461,271,081.01, a 39.21% increase from CNY 1,049,655,125.86 in the previous year[21] - The company plans to distribute a cash dividend of CNY 8.00 per 10 shares, totaling CNY 203,017,982.40, and issue 4 bonus shares for every 10 shares held, resulting in an increase of total shares from 258,952,000 to 360,460,991[4] Production Capacity and Market Position - The company has over 40,000 tons/year production capacity for isothiazolinone industrial biocides, making it the largest producer in Asia[31] - The company has established stable long-term partnerships with key clients such as Lanxess and Osha, enhancing its market position[31] - The company has a total production capacity of over 40,000 tons, making it the largest producer of isothiazolinone industrial biocides in Asia[34] Research and Development - Research and development expenses increased by 17.75% to CNY 47,135,682.63, reflecting the company's commitment to innovation[37] - Total R&D investment amounted to ¥47,135,682.63, representing 3.75% of operating revenue[51] - The number of R&D personnel is 70, accounting for 7.84% of the total workforce[52] Revenue Breakdown - The company's revenue from the chemical raw materials and chemical products sector reached CNY 1,253,335,619.07, with a gross profit margin of 53.10%, an increase of 6.19 percentage points year-on-year[40] - The industrial fungicide segment generated revenue of CNY 1,249,502,279.80, achieving a gross profit margin of 55.69%, which is an increase of 7.67 percentage points compared to the previous year[40] - Domestic revenue amounted to CNY 521,125,094.42, with a gross profit margin of 51.44%, while international revenue was CNY 732,210,524.65, with a gross profit margin of 54.28%[40] Environmental Compliance - The company emphasizes environmental protection and has invested in high-standard facilities to comply with stringent environmental regulations[88] - The company faces increased environmental costs due to stricter regulations, impacting profitability[89] - The company has implemented automatic monitoring systems for both wastewater and exhaust emissions, ensuring compliance with environmental regulations[146] - The company has committed to not engaging in any business activities that compete with its main operations[150] Governance and Management - The company has established a governance structure compliant with relevant laws and regulations, ensuring effective management and investor relations[92] - The company has a structured governance framework with independent directors ensuring compliance and strategic oversight[102] - The company has seen a significant management turnover, with several key personnel changes including the resignation of independent director Yuan Junjie[98] - The company appointed Dahua Accounting Firm as the financial and internal control auditor for the 2022 fiscal year, continuing a four-year relationship[156] Shareholder Information - The largest shareholder, Dalian Tongyun Investment Co., Ltd., holds 77,106,968 shares, accounting for 29.78% of the total shares[176] - Dalian Sanxin Investment Co., Ltd. holds 73,173,220 shares, representing 28.26% of the total shares[176] - The total number of ordinary shareholders as of the end of the reporting period is 13,813, an increase from 13,401 at the end of the previous month[174] Audit and Financial Reporting - The audit report confirmed that the financial statements fairly reflect the company's financial position as of December 31, 2022[194] - The management's policies and methods for revenue recognition were deemed acceptable by the auditors[196] - The company has maintained compliance with accounting standards and has no significant issues reported in the audit[196]

Financial Performance - The company's operating revenue for Q1 2023 was ¥257,856,883.15, representing a decrease of 12.31% compared to the same period last year [3] - The net profit attributable to shareholders for Q1 2023 was ¥72,655,074.26, down 26.21% year-on-year [3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥71,804,390.36, a decline of 26.45% compared to the previous year [3] - Basic earnings per share for Q1 2023 were ¥0.29, down 25.64% from the same period last year [3] - The net profit for Q1 2023 was CNY 72,655,074.26, a decrease of 26.2% compared to CNY 98,465,601.61 in Q1 2022 [15] - Total revenue from operating activities was CNY 219,783,613.73, down 10.0% from CNY 244,334,279.59 in the same period last year [18] - The total profit before tax was CNY 83,488,195.88, down from CNY 117,134,708.98 in the previous year [15] - The company reported a total comprehensive income of CNY 71,180,490.46, down from CNY 98,464,327.84 in Q1 2022 [16] Cash Flow and Liquidity - The net cash flow from operating activities was ¥113,334,039.98, showing a slight decrease of 2.06% year-on-year [3] - Cash and cash equivalents increased to CNY 516,010,928.77 as of March 31, 2023, up from CNY 417,962,525.12 at the end of 2022, indicating improved liquidity [10] - The operating cash flow net amount was CNY 113,334,039.98, slightly down from CNY 115,713,254.47 in Q1 2022 [18] - The net cash flow from investing activities was -¥10,072,692.56, improving from -¥86,632,410.08 in Q1 2022 [26] - The net increase in cash and cash equivalents for Q1 2023 was ¥98,932,364.09, compared to a decrease of -¥36,487,878.77 in Q1 2022 [26] - The ending balance of cash and cash equivalents reached ¥494,115,594.51, significantly up from ¥173,767,264.53 in the previous year [26] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,822,250,531.34, an increase of 3.87% compared to the end of the previous year [3] - Total assets as of March 31, 2023, were CNY 1,822,250,531.34, an increase from CNY 1,754,392,289.92 at the end of 2022 [12] - Total liabilities decreased to CNY 285,987,363.08 from CNY 293,121,208.91, reflecting a reduction in financial obligations [12] - Shareholders' equity increased to CNY 1,536,263,168.26 from CNY 1,461,271,081.01, indicating growth in the company's net worth [12] - Total assets increased to CNY 1,825,185,387.46 as of March 31, 2023, up from CNY 1,757,275,735.91 at the end of 2022, representing a growth of approximately 3.8% [21] - Current assets rose to CNY 1,128,781,988.25, compared to CNY 1,050,281,587.57, marking an increase of about 7.5% [20] Shareholder Information - The top two shareholders hold significant stakes, with 大连通运投资有限公司 owning 29.78% and 大连三鑫投资有限公司 holding 28.26% of shares [6] - The company has a total of 13,401 ordinary shareholders as of the end of the reporting period [6] Research and Development - Research and development expenses were CNY 7,867,543.25, a decrease of 47.2% compared to CNY 14,891,195.96 in the previous year [15] - Research and development expenses decreased to CNY 7,867,543.25 in Q1 2023 from CNY 14,390,713.41 in Q1 2022, a reduction of approximately 45.2% [23] Future Outlook - Future outlook includes potential market expansion and new product development, although specific details were not provided in the financial report [13]

2022 年第三季度报告 证券代码：603360 证券简称：百傲化学 大连百傲化学股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 上年同期增 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 343,558,642.96 | 58.50 | 1,004,001,614.53 | 45.10 | ...

Financial Performance - The company's operating revenue for the first half of 2022 reached RMB 660,442,971.57, representing a 38.98% increase compared to RMB 475,192,916.05 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was RMB 227,587,040.03, an increase of 84.86% from RMB 123,116,314.54 in the previous year[19]. - The net cash flow from operating activities was RMB 190,763,774.39, showing a significant increase of 105.77% compared to RMB 92,706,684.08 in the same period last year[19]. - Basic earnings per share for the first half of 2022 were RMB 0.91, a 93.62% increase compared to RMB 0.47 in the same period last year[20]. - The weighted average return on equity rose to 19.56%, an increase of 7.4 percentage points from 12.16% in the previous year[21]. - The company reported a net profit excluding non-recurring gains and losses of RMB 226,278,023.88, which is an 88.20% increase from RMB 120,234,945.50 in the same period last year[19]. - The diluted earnings per share also stood at RMB 0.91, marking a 93.62% increase compared to RMB 0.47 in the previous year[21]. - Operating profit for the first half of 2022 was ¥267,659,861.76, compared to ¥144,863,414.65 in the first half of 2021, reflecting an increase of 84.8%[98]. - Net profit for the first half of 2022 was ¥227,587,040.03, up 84.9% from ¥123,116,314.54 in the first half of 2021[98]. - Total comprehensive income for the first half of 2022 was ¥246,363,622.26, compared to ¥133,565,634.28 in the first half of 2021, reflecting strong growth[101]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 1,625,211,546.80, a decrease of 2.72% from RMB 1,670,722,296.11 at the end of the previous year[19]. - Total liabilities decreased from ¥621,067,170.25 to ¥343,350,084.56, a decline of approximately 44.7%[91]. - The company's total assets decreased from ¥1,670,722,296.11 to ¥1,625,211,546.80, a reduction of about 2.7%[91]. - The company's retained earnings increased from ¥656,429,160.01 to ¥884,016,200.04, reflecting a growth of approximately 34.6%[91]. - The total equity increased to ¥1,384,170,913.10 from ¥1,133,201,098.34, indicating a growth of 22.1%[95]. Production Capacity and Market Position - The company has over 40,000 tons/year of production capacity for isothiazolinone industrial biocides, making it the largest producer in Asia[24]. - Sales revenue from isothiazolinone industrial biocides accounted for 99.72% of the company's total revenue, providing stable cash flow[28]. - The company has established stable long-term partnerships with major clients such as Lanxess and Oshaida, enhancing its market position[24]. - The company has a flexible production model that allows for capacity adjustments based on sales plans, ensuring timely product supply[28]. Research and Development - Research and development expenses increased by 116.12% to 31.14 million RMB, reflecting the company's commitment to innovation[34]. - The company has been recognized as a high-tech enterprise since October 2011, holding multiple invention patents and a strong R&D team[29]. - The company plans to continue its focus on research and development in new chemical products to enhance market competitiveness[123]. Environmental Compliance and Safety - The company maintains a high standard of safety and environmental protection, complying with national and local environmental quality standards[29]. - The company reported a chemical oxygen demand (COD) discharge of 40.48 tons, which is compliant with environmental standards[58]. - The company’s nitrogen oxides emissions were recorded at 5.156 tons, also meeting the required standards[58]. - The company has completed the revision of the emergency response plan for environmental incidents in May 2022, which has been filed with the local environmental bureau[63]. - The company has established a hazardous waste disposal process that complies with relevant laws and regulations[62]. Shareholder and Stock Information - The company reported a total share count of 258,952,000 after a reduction of 2,394,400 shares, representing a decrease of approximately 0.92%[72]. - The top shareholder, Dalian Tongyun Investment Co., Ltd., held 77,106,968 shares, accounting for 29.78% of total shares, with 38,800,000 shares pledged[79]. - The company repurchased and canceled a total of 2,394,400 restricted shares due to performance assessment not meeting targets and the departure of 4 incentive plan participants, reducing total shares from 26,134,640 to 25,895,200[74]. - The company has implemented a stock incentive plan, although there have been no recent developments[54]. Financial Strategy and Cash Flow - The company incurred financial expenses of -¥9,966,883.98, a significant improvement compared to ¥554,300.05 in the previous year[100]. - The company received CNY 50,000,000.00 in borrowings during the first half of 2022, a significant decrease from CNY 398,485,572.00 in the same period of 2021, indicating a shift in financing strategy[107]. - The total cash inflow from financing activities was CNY 127,413,774.31, down from CNY 588,776,932.00 in the previous year, reflecting a decrease of 78.4%[107]. Governance and Compliance - The company received a disciplinary notice from the Shanghai Stock Exchange on May 18, 2022, involving the actual controller and financial director[68]. - There were no significant lawsuits or arbitration matters reported during the period[68]. - The financial statements were approved by the board of directors on August 15, 2022, ensuring compliance with regulatory requirements[124]. - The company has not identified any significant doubts regarding its ability to continue as a going concern for the next 12 months[127].

Financial Performance - The company's operating revenue for 2021 was approximately CNY 1,006.26 million, representing a 34.25% increase compared to CNY 749.54 million in 2020[22]. - The net profit attributable to shareholders for 2021 was CNY 250.49 million, a 12.96% increase from CNY 221.75 million in 2020[22]. - The net profit after deducting non-recurring gains and losses was CNY 253.48 million, up 17.98% from CNY 214.84 million in 2020[22]. - The basic earnings per share increased to CNY 1.00, a rise of 17.65% compared to CNY 0.85 in the previous year[24]. - The diluted earnings per share also rose to CNY 0.99, reflecting a 16.47% increase from the previous year[24]. - The weighted average return on equity improved to 25.12%, an increase of 4.38 percentage points from 20.74% in 2020[24]. - The company reported a total revenue of 1.5 billion in 2021, representing a year-over-year growth of 15%[101]. - The company’s revenue reached 1,006.26 million yuan, a year-on-year growth of 34.25%, while the net profit attributable to shareholders was 250.49 million yuan, up 12.96%[89]. Cash Flow and Assets - The net cash flow from operating activities decreased by 32.57% to CNY 142.03 million from CNY 210.62 million in 2020[22]. - Total assets at the end of 2021 reached CNY 1,670.72 million, a 16.86% increase from CNY 1,429.70 million at the end of 2020[23]. - The company reported a significant increase in accounts receivable by 51.62% to ¥187,302,822.42 in 2021 from ¥123,535,361.89 in 2020[56]. - Inventory rose by 75.98% to ¥186,731,620.50 in 2021 from ¥106,110,749.77 in 2020, reflecting increased production capacity from the completion of the Songmu Island Phase III project[56]. - Fixed assets increased by 104.11% to ¥737,696,026.55 in 2021 from ¥361,426,530.34 in 2020, due to the completion and capitalization of the Songmu Island Phase III project[56]. Production Capacity and Operations - The company has over 40,000 tons/year of production capacity for isothiazolinone industrial biocides, solidifying its position as the largest producer in Asia[32]. - The company completed the construction of the third phase project at the Songmu Island subsidiary, which began trial production in September 2021[32]. - The production of CIT/MIT series products has a capacity of 12,000 tons, while MIT series products have a capacity of 2,000 tons[37]. - The company achieved an industrial biocide output of 41,208.71 tons, representing a year-on-year increase of 16.51%, with a capacity utilization rate of 101.56%[89]. - The completion of the third phase project at Songmu Island has added production capacity of 12,000 tons/year for CIT/MIT, 2,000 tons/year for MIT, 1,200 tons/year for OIT, and 2,500 tons/year for BIT, bringing the total industrial biocide capacity to 40,000 tons/year[73]. Research and Development - The company invested 40,031,669.69 RMB in R&D, reflecting a 40.12% increase from the previous year[41]. - Research and development expenditures over the past three years were 28.14 million yuan, 28.57 million yuan, and 40.03 million yuan, accounting for 3.23%, 3.81%, and 3.98% of operating income respectively, indicating a steady increase in both absolute and relative terms[87]. - The company has developed over 50 formula products, with more than 30 currently on sale, which have higher sales prices and gross profit margins compared to raw materials[88]. Market and Sales - Approximately 50% of the company's revenue comes from international clients, with major clients including global chemical giants such as Lanxess and Oshada[88]. - The company plans to continue seeking international partnerships to enhance brand recognition and expand its market share globally[88]. - The sales model is primarily direct sales, targeting technical service providers and industrial biocide traders[36]. Governance and Compliance - The company has established a comprehensive corporate governance structure in compliance with relevant laws and regulations, ensuring good investor relations and effective information disclosure[95]. - The company has maintained a focus on enhancing its internal control systems to improve governance quality[95]. - The company has not reported any significant changes in the competitive landscape or measures taken to address potential conflicts of interest with controlling shareholders[95]. - The company has not disclosed any significant related party transactions during the reporting period, indicating a focus on transparency[167]. Environmental Responsibility - The company reported a chemical oxygen demand (COD) wastewater discharge of 54 tons from its Songmu Island subsidiary, which met the environmental standards[136]. - The company’s Lushun subsidiary reported a COD wastewater discharge of 3.998 tons, also in compliance with environmental standards[138]. - The company has installed automatic monitoring facilities for pollutants at discharge points, with all monitored pollutants meeting discharge standards[144]. - The company has completed the environmental impact assessments for construction projects and has not faced penalties from regulatory authorities[145]. Risks and Challenges - The company faces risks related to environmental protection, safety production, raw material price fluctuations, and exchange rate volatility, which could impact operational performance[91][92]. - The company has acknowledged the existence of non-operating fund occupation by controlling shareholders and their affiliates[8]. - The company has reported a significant increase in freight costs, which rose by 98.95% year-on-year to approximately ¥51.65 million, indicating higher logistics expenses[47]. Future Outlook - The company provided a future outlook, projecting a revenue growth of 10% for the next fiscal year, targeting 1.65 billion[101]. - The company anticipates continued growth in the domestic application market for isothiazolinone biocides, despite challenges from raw material price fluctuations and global pandemic impacts[85].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 294,068,308.89, representing a year-on-year increase of 34.65%[2] - The net profit attributable to shareholders was CNY 98,465,601.61, reflecting an increase of 89.97% compared to the same period last year[2] - Basic earnings per share were CNY 0.39, marking a 95.00% increase from the previous year[2] - The net profit after deducting non-recurring gains and losses was CNY 97,622,683.95, up 92.41% year-on-year[2] - The net profit for Q1 2022 was CNY 98,465,601.61, representing a 90% increase compared to CNY 51,831,316.56 in Q1 2021[18] - Operating profit for Q1 2022 reached CNY 117,161,373.68, up from CNY 61,054,786.14 in the same period last year, indicating a growth of approximately 92%[18] - The total comprehensive income for Q1 2022 was CNY 98,464,327.84, compared to CNY 51,831,316.56 in Q1 2021, indicating a substantial increase[19] Cash Flow - The net cash flow from operating activities reached CNY 115,713,254.47, up by 146.95% year-on-year[2] - Cash flow from operating activities for Q1 2022 was CNY 115,935,294.28, significantly higher than CNY 57,526,819.63 in Q1 2021, indicating a 101% increase[30] - The company reported a cash and cash equivalents balance of CNY 174,333,494.91 at the end of Q1 2022, compared to CNY 165,194,669.93 at the end of Q1 2021[23] - The cash and cash equivalents decreased by $36,487,878.77 during the period, compared to a decrease of $14,104,752.16 in the prior period[31] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,843,367,714.24, a 10.33% increase from the end of the previous year[3] - Total assets reached RMB 1,843,367,714.24 as of March 31, 2022, compared to RMB 1,670,722,296.11 at the end of 2021, marking a growth of 10.3%[14] - Total liabilities as of March 31, 2022, were RMB 692,945,164.29, up from RMB 621,067,170.25 at the end of 2021, reflecting an increase of 11.6%[13] - The company's total liabilities decreased to CNY 529,547,694.94 in Q1 2022 from CNY 551,951,327.46 in Q1 2021, a reduction of about 4%[26] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,026[6] - Major shareholder Dalian Tongyun Investment Co., Ltd. held 29.50% of the shares, with 38,800,000 shares pledged[7] Research and Development - Research and development expenses in Q1 2022 amounted to RMB 14,891,195.96, significantly higher than RMB 6,142,918.54 in Q1 2021, indicating a 142.5% increase[17] - Research and development expenses increased significantly to CNY 14,390,713.41, up from CNY 5,612,029.90 in the previous year, marking a 156% rise[28] Operating Costs - Total operating costs for Q1 2022 were RMB 178,026,084.85, up from RMB 151,813,050.45 in Q1 2021, reflecting a year-over-year increase of 17.4%[17] - The company's operating expenses, including sales and management costs, totaled CNY 39,073,204.35 in Q1 2022, compared to CNY 20,756,356.47 in Q1 2021, reflecting an increase of 88%[28] Financial Position - The weighted average return on equity increased by 3.69 percentage points to 8.96%[2] - The total equity of the company as of Q1 2022 was CNY 1,241,084,742.59, compared to CNY 1,133,201,098.34 in Q1 2021, showing an increase of approximately 10%[26] Investment Activities - Investment activities resulted in a net cash outflow of CNY 86,736,221.83 in Q1 2022, compared to a net outflow of CNY 77,700,663.70 in Q1 2021[22] - The cash outflow related to investment activities was $87,365,672.82, compared to $99,325,373.33 in the previous period[31]

Financial Performance - The company's operating revenue for Q3 2021 was CNY 216,757,283.85, representing a year-on-year increase of 28.14%[5] - The net profit attributable to shareholders for Q3 2021 was CNY 37,016,596.19, a decrease of 27.20% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 35,060,722.47, down 27.78% year-on-year[5] - The basic earnings per share for Q3 2021 was CNY 0.14, a decrease of 26.32% compared to the previous year[6] - The company achieved a revenue of CNY 691,950,199.90 for the year-to-date period, with a growth of 22.07% compared to the previous year[5] - Net profit for the first three quarters of 2021 was ¥160,132,910.73, compared to ¥178,809,189.22 in the same period of 2020, reflecting a decrease of approximately 10.5%[19] - The net profit attributable to the parent company for Q3 2021 was ¥160,132,910.73, a decrease of 10.5% compared to ¥178,809,189.22 in Q3 2020[20] - The total comprehensive income for Q3 2021 was ¥160,129,604.32, down from ¥178,818,813.85 in Q3 2020, indicating a decline of 10.5%[20] Cash Flow and Assets - The cash flow from operating activities for the year-to-date period was CNY 110,730,001.27, showing a decline of 37.70%[6] - Cash flow from operating activities for the first nine months of 2021 was ¥110,730,001.27, a decrease of 37.7% compared to ¥177,745,793.52 in the same period of 2020[24] - The company's cash and cash equivalents decreased to ¥259,973,709.50 from ¥333,068,462.74, a decline of about 22.0%[15] - The cash and cash equivalents at the end of Q3 2021 were ¥171,751,306.49, a decrease from ¥340,900,855.18 at the end of Q3 2020[25] - The company's total assets as of September 30, 2021, amounted to ¥1,575,314,359.12, an increase from ¥1,429,695,956.74 at the end of 2020, showing a growth of about 10.2%[16] Costs and Expenses - Total operating costs for the first three quarters of 2021 were ¥504,962,989.47, up from ¥365,746,716.33 in 2020, indicating an increase of about 38.1%[18] - The company reported a financial expense of ¥4,875,748.81 for the first three quarters of 2021, compared to ¥3,276,229.29 in 2020, representing an increase of about 48.8%[19] - Research and development expenses for the first three quarters of 2021 were ¥24,939,361.32, up from ¥19,438,181.25 in 2020, indicating an increase of approximately 28.6%[19] Equity and Liabilities - Current liabilities totaled ¥571,927,752.96 as of September 30, 2021, compared to ¥396,049,476.04 at the end of 2020, representing an increase of approximately 44.2%[16] - The total equity attributable to shareholders decreased to ¥961,270,047.38 from ¥988,283,192.35, a decline of approximately 2.7%[16] Business Strategy - The company plans to adjust product prices in response to fluctuations in raw material costs to alleviate cost pressures[12] - The industrial biocide business continues to show stable growth, although profit growth has slowed due to rising raw material prices[12] Cash Flow from Activities - Total cash inflow from investing activities was ¥10,365,250.00, while cash outflow was ¥173,777,347.45, resulting in a net cash outflow of ¥163,412,097.45 for the first nine months of 2021[25] - Cash inflow from financing activities for the first nine months of 2021 was ¥640,271,307.00, significantly higher than ¥330,000,000.00 in the same period last year, marking an increase of 94.5%[25] - The net cash flow from financing activities was ¥45,211,675.42, compared to a minimal increase of ¥353,425.32 in the same period of 2020[25] Other Comprehensive Income - The company received ¥23,159,625.54 in tax refunds related to operating activities, an increase from ¥10,184,577.94 in the same period last year[24] - The company reported a decrease in other comprehensive income after tax, with a net amount of -¥3,306.41 for Q3 2021 compared to ¥9,624.63 in Q3 2020[20]